ASKA Pharmaceutical Holdings Co.,Ltd.

4886 TSE Pharmaceuticals Pharmaceutical
TSE Prime
¥2,040.00
-0.83%
Delayed · cached 15 min

Fair value analysis

4886
ASKA Pharmaceutical Holdings Co.,Ltd.
Pharmaceuticals›Pharmaceutical
¥2,040.00
Close used for this calculation
¥2,733.85Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
70/100
Profitability13/25
Returns13/25
Balance Sheet21/25
Efficiency23/25
Growth14/25
Strong
Quality radar
70Prof.13/25Ret.13/25Eff.23/25B.Sht21/25Growth14/25

Consensus fair value

¥2,733.85
Below FV
▲ +34.0% against the close used
Model range ¥1,154.36 – ¥3,822.40
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥1,154.36Fair value¥2,733.85Bull¥3,822.40
FairClose
52-week traded range
52W low ¥1,929.0052W high ¥2,995.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

ASKA Pharmaceutical Holdings Co.,Ltd. closed at ¥2,040.00, 25.4% below the consensus fair value of ¥2,733.85 drawn from 9 valuation models.

Financial DNA score 70/100 — Strong. P/E of 10.7x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
¥2,215.01
+8.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=6%, r=10%, tg=3%, n=10yr
Graham Number
¥3,270.79
+60.3%
√(22.5 × EPS × BVPS)
EPS=191.12, BVPS=2487.8
P/E Fair Value
¥3,822.40
+87.4%
EPS × 20x (sector P/E)
EPS=191.12, Sector P/E=20x
Peter Lynch (PEG)
¥1,154.36
-43.4%
EPS × Growth% (PEG = 1 is fair)
EPS=191.12, g=6%
EV/EBITDA
¥3,666.87
+79.7%
(EBITDA × 13x − Net Debt) ÷ Shares
EBITDA=8.75B
Dividend Discount (DDM)
¥1,606.02
-21.3%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=59.98, r=10%, g=6%
Book Value (P/B)
¥1,243.90
-39.0%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=2487.8, ROE=8%, g=6%, r=10%
Reverse DCF
¥2,040.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -1.4% | Historical: 6%
Margin of Safety
¥2,327.05
+14.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=3102.73, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.